ADMA Biologics (ADMA)
US Market

ADMA Biologics Income Statement


ADMA Biologics Income Statement

Last quarter (Q3 2022), ADMA Biologics's total revenue was $41.09M, an increase of 98.69% from the same quarter last year. In Q3, ADMA Biologics's net income was $-14.90M. See ADMA Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 130.48M$ 80.94M$ 42.22M$ 29.35M$ 16.99M$ 22.76M
Cost of Revenue
$ 105.88M$ 79.77M$ 61.29M$ 39.50M$ 42.19M$ 29.16M
Gross Profit
$ 24.60M$ 1.17M$ -19.07M$ -10.16M$ -25.21M$ -6.40M
Operating Expense
$ 71.10M$ 59.55M$ 45.84M$ 31.27M$ 35.08M$ 32.06M
Operating Income
$ -46.50M$ -58.37M$ -64.91M$ -41.42M$ -60.29M$ -38.46M
Net Non Operating Interest Income Expense
$ -16.81M$ -13.02M$ -11.70M$ -8.19M$ -5.33M$ -3.23M
Other Income Expense
$ -7.01M$ -251.57K$ 863.27K$ 1.34M$ -127.12K$ -2.07M
Pretax Income
$ -70.32M$ -71.65M$ -75.75M$ -48.28M$ -65.74M$ -43.76M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -70.32M$ -71.65M$ -75.75M$ -48.28M$ -65.74M$ -43.76M
Basic EPS
$ -0.37$ -0.51$ -0.88$ -0.89$ -1.45$ -1.91
Diluted EPS
$ -0.37$ -0.51$ -0.88$ -0.89$ -1.45$ -1.91
Basic Average Shares
$ 769.88M$ 139.58M$ 86.15M$ 54.35M$ 45.19M$ 22.90M
Diluted Average Shares
$ 769.88M$ 139.58M$ 86.15M$ 54.35M$ 45.19M$ 22.90M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 176.98M$ 139.32M$ 107.13M$ 70.77M$ 77.27M$ 61.23M
Net Income From Continuing And Discontinued Operation
$ -70.32M$ -71.65M$ -75.75M$ -48.28M$ -65.74M$ -43.76M
Normalized Income
$ -63.65M$ -71.65M$ -76.74M$ -49.84M$ -65.74M$ -41.70M
Interest Expense
$ 16.86M$ 13.06M$ 11.99M$ 8.99M$ 5.52M$ 3.29M
$ -53.46M$ -58.59M$ -63.76M$ -39.29M$ -60.22M$ -40.47M
$ -46.77M$ -53.10M$ -59.82M$ -36.03M$ -56.77M$ -37.78M
Currency in USD

ADMA Biologics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis